Next |
home / stock / lctx / lctx message board
Subject | By | Source | When |
---|---|---|---|
https://www.mdpi.com/2079-7737/12/5/653 | chrismiss_everyday | investorshub | 04/30/2023 11:54:42 AM |
NEWS -- RG6501 (OpRegen®) Phase 1/2a Clinical Results | Paulness | investorshub | 04/26/2023 1:22:54 PM |
April 26, 2023 8:00 AM EDT | chrismiss_everyday | investorshub | 04/26/2023 1:03:46 PM |
A systems biology approach uncovers novel disease mechanisms | chrismiss_everyday | investorshub | 04/21/2023 12:44:56 PM |
ZZZZZZZZZZZZZ | abracky | investorshub | 04/18/2023 3:37:54 PM |
NEWS -- Lineage to Present at 2023 AAPS | Paulness | investorshub | 04/18/2023 12:27:33 PM |
https://www.christopherreeve.org/about-us/press-releases/lineage-and-the-christo | chrismiss_everyday | investorshub | 04/15/2023 10:11:19 PM |
https://investor.lineagecell.com/news-releases/news-release-details/lineage-and- | chrismiss_everyday | investorshub | 03/30/2023 1:11:09 PM |
NEWS -- RG6501 (OpRegen) Phase 1/2a Clinical Results | Paulness | investorshub | 03/20/2023 12:12:09 PM |
https://investor.lineagecell.com/node/22796/html 150,000 shares for Jillian H | chrismiss_everyday | investorshub | 03/11/2023 12:20:21 AM |
More durable and reliable progress. Good stuff. ARVO | chrismiss_everyday | investorshub | 03/10/2023 10:52:19 PM |
NEWS -- Q4 2022 Lineage Cell Therapeutics Inc | Paulness | investorshub | 03/10/2023 1:43:59 PM |
8K and 10K | chrismiss_everyday | investorshub | 03/10/2023 11:38:44 AM |
NEWS -- RG6501 (OpRegen) Phase 1/2a Results to | Paulness | investorshub | 03/06/2023 2:22:35 PM |
NEWS -- Lineage Cell Therapeutics to Report Fourth | Paulness | investorshub | 03/02/2023 2:17:12 PM |
NEWS -- Lineage Enters Into Option and License | Paulness | investorshub | 02/22/2023 2:44:39 PM |
Thanks for posting this Paulnessmissed it in my | chrismiss_everyday | investorshub | 02/09/2023 6:28:56 PM |
NEWS -- Lineage Provides Update on Auditory Neuronal | Paulness | investorshub | 02/08/2023 2:11:54 PM |
Presentation is up | chrismiss_everyday | investorshub | 01/23/2023 2:32:03 PM |
NEWS -- Lineage to Present at BTIG Ophthalmology | Paulness | investorshub | 11/29/2022 1:15:06 PM |
News, Short Squeeze, Breakout and More Instantly...
BioTime Inc. Company Name:
LCTX Stock Symbol:
NYSE Market:
Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit OpRegen Preclinical Results Pre...
BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10) BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5) Maintenance or increases in external limiting membrane (ELM) and retinal pigment epithelium (RPE) laye...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the...